Cormorant Asset Management, LP Uro Gen Pharma Ltd. Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 300,000 shares of URGN stock, worth $3.02 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
300,000
Previous 1,550,000
80.65%
Holding current value
$3.02 Million
Previous $19.7 Million
83.77%
% of portfolio
0.25%
Previous 1.38%
Shares
3 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$38.7 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$29.5 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$23.2 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$22.1 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$17.6 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $229M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...